Keros Therapeutics, INC 10-Q quarterly reports

Keros Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development, financial performance, and risk factors.

Keros Therapeutics reports a net loss of $23.7 million for Q1 2026, a significant decrease from the prior year's net income, primarily due to the absence of a large upfront licensing payment.

Keros Therapeutics reported a net loss of $7.3 million for Q3 2025, alongside a $110.5 million net income for the nine months ended September 30, 2025, driven by the Takeda license agreement, and announced a $375 million capital return plan to stockholders.

Keros Therapeutics announced a significant net income for the first half of 2025 driven by a major licensing deal with Takeda, alongside a planned $375 million capital return to stockholders and a workforce reduction.

Keros Therapeutics reports a net income of $148.5 million for Q1 2025, primarily driven by revenue from its licensing agreement with Takeda, while advancing its clinical pipeline.

Keros Therapeutics reports a net loss of $53.0 million for the third quarter of 2024, while highlighting progress in its clinical programs for elritercept, cibotercept, and KER-065.

Keros Therapeutics reports a net loss of $45.3 million for the second quarter of 2024, while advancing its clinical programs for elritercept, cibotercept, and KER-065.

Keros Therapeutics reports a net loss of $43.1 million for the first quarter of 2024, alongside updates on its clinical trials for KER-050, KER-012, and KER-065.